The stock of Immune Design Corp (NASDAQ:IMDZ) reached all time low today, Oct, 28 and still has $5.16 target or 11.00% below today’s $5.80 share price. This indicates more downside for the $144.94 million company. This technical setup was reported by Barchart.com. If the $5.16 PT is reached, the company will be worth $15.94 million less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only. About 25,267 shares traded hands. Immune Design Corp (NASDAQ:IMDZ) has declined 46.40% since March 28, 2016 and is downtrending. It has underperformed by 51.11% the S&P500.
Analysts await Immune Design Corp (NASDAQ:IMDZ) to report earnings on November, 10. They expect $-0.68 earnings per share, down 83.78% or $0.31 from last year’s $-0.37 per share. After $-0.71 actual earnings per share reported by Immune Design Corp for the previous quarter, Wall Street now forecasts -4.23% EPS growth.
Immune Design Corp (NASDAQ:IMDZ) Ratings Coverage
Out of 2 analysts covering Immune Design (NASDAQ:IMDZ), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Immune Design has been the topic of 4 analyst reports since August 18, 2015 according to StockzIntelligence Inc. The rating was initiated by Jefferies with “Buy” on Wednesday, September 9. Jefferies maintained the stock with “Buy” rating in Wednesday, August 10 report. Leerink Swann initiated Immune Design Corp (NASDAQ:IMDZ) on Tuesday, August 18 with “Outperform” rating.
According to Zacks Investment Research, “Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on the development of immune-based therapies based on its DCVex (TM) and GLAAS (TM) discovery platforms for cancer and other chronic conditions. Its product candidates in Phase I clinical trials comprise LV305, CMB305, and G305 for the treatment of solid tumor types, such as breast cancer, melanoma, non-small cell lung cancer, ovarian cancer, or sarcoma; and G100 for the treatment of patients with merkel cell carcinoma. Immune Design Corp. is headquartered in Seattle, Washington.”
Insitutional Activity: The institutional sentiment increased to 1.25 in 2016 Q2. Its up 0.21, from 1.04 in 2016Q1. The ratio is positive, as 8 funds sold all Immune Design Corp shares owned while 16 reduced positions. 8 funds bought stakes while 22 increased positions. They now own 9.57 million shares or 12.34% less from 10.92 million shares in 2016Q1.
Pnc Fin Group Incorporated, a Pennsylvania-based fund reported 76 shares. Tiaa Cref Management Limited Co last reported 43,523 shares in the company. Moreover, Rhumbline Advisers has 0% invested in Immune Design Corp (NASDAQ:IMDZ) for 10,089 shares. The New York-based Tower Research Ltd Liability Corporation (Trc) has invested 0% in Immune Design Corp (NASDAQ:IMDZ). The New York-based Jpmorgan Chase & has invested 0% in Immune Design Corp (NASDAQ:IMDZ). Barclays Public Ltd Co holds 264 shares or 0% of its portfolio. Point72 Asset Mgmt Ltd Partnership holds 70,572 shares or 0% of its portfolio. Cormorant Asset Limited Liability reported 432,990 shares or 0.5% of all its holdings. Northern Corporation last reported 0% of its portfolio in the stock. Blackrock Inc has 0% invested in the company for 3,163 shares. Amer Gru Inc holds 0% or 6,440 shares in its portfolio. Teacher Retirement System Of Texas, a Texas-based fund reported 1,129 shares. Fincl Bank Of New York Mellon Corp has 0% invested in the company for 59,438 shares. Blackrock Fund Advsrs has 0% invested in the company for 549,736 shares. Proquest Associates Iv Ltd Company accumulated 6.51% or 1.96 million shares.
Insider Transactions: Since July 15, 2016, the stock had 4 buys, and 0 selling transactions for $10.26 million net activity. Brady Stephen R bought 1,500 shares worth $10,255. $5.00 million worth of Immune Design Corp (NASDAQ:IMDZ) was bought by Svennilson Peter on Tuesday, September 20. On Tuesday, September 20 COLUMN GROUP L P bought $5.00M worth of the stock or 800,000 shares. $250,000 worth of Immune Design Corp (NASDAQ:IMDZ) was bought by COLEMAN LEWIS W.
More important recent Immune Design Corp (NASDAQ:IMDZ) news were published by: Quotes.Wsj.com which released: “News Immune Design Corp.IMDZ” on July 23, 2014, also Gurufocus.com published article titled: “Immune Design Insider Buys Shares”, Globenewswire.com published: “Immune Design and Gritstone Oncology Announce Clinical Collaboration for …” on May 09, 2016. More interesting news about Immune Design Corp (NASDAQ:IMDZ) was released by: Globenewswire.com and their article: “Immune Design Announces Presentations at the 2016 American Society of Clinical …” with publication date: April 21, 2016.
IMDZ Company Profile
Immune Design Corp., incorporated on February 20, 2008, is a clinical-stage immunotherapy company. The Firm focuses on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Firm is developing multiple product candidates from its discovery platforms, including ZVex and GLAAS. ZVex is a discovery platform that uses a vector to generate product candidates designed to create cytotoxic T cells (CTLs) in vivo. The ZVex vector is a delivery system based on a hybrid, re-engineered virus designed to carry the genetic information of selected tumor antigen in whole or selected epitopes selectively to dendritic cells (DCs) in the skin. When injected into a cancer patient, a ZVex product candidate is designed to interact only with these DCs, delivering the tumor antigen in the form of ribonucleic acid (RNA).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.